Horizon Therapeutics plc is a global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. The Company operates through two segments: orphan segment and the inflammation segment. The orphan segment includes medicines, such as TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase injection), RAVICTI (glycerol phenylbutyrate), PROCYSBI (cysteamine bitartrate), UPLIZNA (inebilizumab-cdon) injection, ACTIMMUNE (interferon gamma-1b) injection, BUPHENYL (sodium phenylbutyrate) tablets and powder, and QUINSAIR (levofloxacin) solution. The inflammation segment includes medicines, such as PENNSAID (diclofenac sodium topical solution), RAYOS (prednisone), VIMOVO (naproxen), and DUEXIS (ibuprofen).
During the most recent quarter, 750 shares were bought, and 62K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.